13 completed, 3 terminated, 3 unknown, 2 active not recruiting. 22 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 13, Terminated 3, Unknown 3, Active not recruiting 2, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow Prostatic Neoplasm: new trials by email Literature Review of Prostatic Neoplasm trials Research Report on Prostatic Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness Dietary recommendations, Time-restricted eating - Prostatic Neoplasm, Survivorship | Phase 1 / Phase 2 | Active not recruiting | University of Maryland, Baltimore | 30 | 2024-01-29 | 2026-01-27 |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC AAA617, AAA517, Piflufolastat F 18 - Prostatic Neoplasm | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 49 | 2024-01-03 | 2026-10-21 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP salvage SBRT - Prostatic Neoplasm | Phase 2 | Unknown | Regina Elena Cancer Institute | 103 | 2022-09-27 | 2022-12-28 |
| Trial of NanoPac Focal Therapy for Prostate Cancer NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Terminated | NanOlogy, LLC | 1 | 2020-10-20 | 2022-03-29 |
| HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy - Prostatic Neoplasm | Phase 2 | Unknown | David Büchser | 50 | 2019-07-01 | 2020-08-24 |
| I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). I-131-1095, Enzalutamide - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Completed | Progenics Pharmaceuticals, Inc. | 120 | 2019-05-30 | 2025-10-14 |
| Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. Estetrol, Placebo Oral Tablet - Prostatic Neoplasm | Phase 2 | Completed | Pantarhei Oncology B.V. | 63 | 2018-04-16 | 2021-06-18 |
| 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer Ga-68 PSMA-HBED-CC PET - Prostate Cancer, Prostatic Neoplasm | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 30 | 2018-02-16 | 2024-07-12 |
| 68Ga PSMA in Preprostatectomy Patients Ga-68 PSMA-HBED-CC PET - Prostate Cancer, Prostatic Neoplasm | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 22 | 2018-02-16 | 2024-02-15 |
| An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma Docetaxel, Androgen-Deprivation Therapy (ADT) - Prostatic Neoplasm | Phase 2 | Unknown | Samsung Medical Center | 42 | 2017-02-08 | 2022-03-08 |
| Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study Perflutren Lipid Microsphere Intravenous Suspension - Prostatic Neoplasm | Phase 2 | Completed | Thomas Jefferson University | 55 | 2017-02-01 | 2025-04-30 |
| Carboplatin in Castration-resistant Prostate Cancer Carboplatin - Prostatic Neoplasm | Phase 2 | Terminated | Aurelius Omlin | 16 | 2015-02-01 | 2020-01-23 |
| Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate Metformin, Placebo - Prostatic Neoplasm | Phase 2 | Terminated | AHS Cancer Control Alberta | 83 | 2014-09-01 | 2024-01-30 |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer sipuleucel-T, leuprolide acetate - Prostatic Neoplasm, Prostate Cancer | Phase 2 | Completed | Dendreon | 68 | 2011-09-01 | 2017-05-30 |
| IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen abiraterone acetate in combination with prednisone - Prostate Cancer, Prostatic Neoplasm | Phase 2 | Completed | Janssen Biotech, Inc. | 131 | 2011-05-04 | 2026-02-24 |
| Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer radioimmuniguided intenstiy modulated radiotherapy - Prostatic Neoplasm | Phase 1 / Phase 2 | Completed | Mayo Clinic | 72 | 2006-10-01 | 2011-02-25 |
| Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer SR31747A - Prostatic Neoplasm | Phase 2 | Completed | Sanofi | 232 | 2003-10-01 | 2008-12-23 |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy STI571 (Glivec®) - Prostatic Neoplasm, Genital Neoplasms, Male | Phase 2 | Completed | Novartis Pharmaceuticals | 51 | 2003-06-01 | 2017-06-01 |
| Preop Conformal Radiotherapy - Prostate Pre-Operative Conformal Radiotherapy - Prostatic Neoplasm | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 15 | 2000-05-01 | 2010-08-11 |
Showing 20 of 22. Sign in to see all of them.
Prostatic Neoplasms (22) · Genital Neoplasms, Male (3) · Neoplasms (3) · Urogenital Neoplasms (3) · Prostatic Diseases (2) · Prostatic Neoplasms, Castration-Resistant (2) · Abdominal Neoplasms (1) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Frailty (1) · Gallbladder Neoplasms (1) · Genital Diseases, Male (1) · Hematologic Neoplasms (1)
Genital Diseases (22) · Male Urogenital Diseases (22) · Neoplasms by Site (22) · Urogenital Diseases (22) · Genital Diseases, Male (21) · Prostatic Diseases (20) · Genital Neoplasms, Male (19) · Neoplasms (19) · Urogenital Neoplasms (19) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Carboplatin (1) · Docetaxel (1) · Estetrol (1) · Imatinib Mesylate (1) · Leuprolide (1) · Lutetium (1) · Lutetium-177 (1) · Metformin (1) · Paclitaxel (1) · Pluvicto (1) · Powders (1) · Prednisone (1)
Michael Graham PhD, MD (2) · National Cancer Institute (NCI) (2) · Novartis Pharmaceuticals (2) · AHS Cancer Control Alberta (1) · Aurelius Omlin (1) · Cancer Research UK (1) · David Büchser (1) · Dendreon (1) · Janssen Biotech, Inc. (1) · Mayo Clinic (1) · NanOlogy, LLC (1) · Pantarhei Oncology B.V. (1) · Progenics Pharmaceuticals, Inc. (1) · Regina Elena Cancer Institute (1) · Samsung Medical Center (1)
United States (12) · Canada (5) · Italy (3) · Spain (3) · Czechia (2) · France (2) · Germany (2) · Netherlands (2) · Poland (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Chile (1)
Alfonso Gomez-Iturriaga, MD, PhD (1) · Amber Kleckner, PhD (1) · Aurelius G Omlin, MD (1) · Ethan J Halpern, MD (1) · Flemming Forsberg, PhD (1) · Jean-Claude Provost, MD (1) · Matthew Krebs, Dr (1) · Michael Graham, MD, PhD (1) · Michael M. Graham, MD, PhD (1) · Nawaid Usmani, MD (1) · Padraig Warde, MD (1)
R21CA202214 (1)